0001140361-23-028161.txt : 20230602 0001140361-23-028161.hdr.sgml : 20230602 20230602200615 ACCESSION NUMBER: 0001140361-23-028161 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230531 FILED AS OF DATE: 20230602 DATE AS OF CHANGE: 20230602 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SEIDENBERG BETH C CENTRAL INDEX KEY: 0001184592 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36548 FILM NUMBER: 23990948 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Atara Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001604464 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 460920988 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2380 CONEJO SPECTRUM ST STREET 2: SUITE 200 CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: 805-623-4244 MAIL ADDRESS: STREET 1: 2380 CONEJO SPECTRUM ST STREET 2: SUITE 200 CITY: THOUSAND OAKS STATE: CA ZIP: 91320 4 1 form4.xml X0407 4 2023-05-31 0001604464 Atara Biotherapeutics, Inc. ATRA 0001184592 SEIDENBERG BETH C C/O ATARA BIOTHERAPEUTICS, INC. 2380 CONEJO SPECTRUM ST, SUITE 200 THOUSAND OAKS CA 91320 true false Common Stock 2023-05-31 4 A 0 57000 0 A 115689 D Common Stock 1822228 I See footnote Common Stock 54422 I See footnote Common Stock 197 I See footnote Common Stock 197 I See footnote Non-Qualified Stock Option (Right to Buy) 1.53 2023-05-31 4 A 0 79500 0 A 2033-05-30 Common Stock 79500 79500 D These restricted stock units shall vest on the earlier of May 31, 2024 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. The option shall vest on the earlier of May 31, 2024 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. The shares are directly held by Kleiner Perkins Caufield & Byers XV, LLC ("KPCB XV"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XV is KPCB XV Associates, LLC ("XV Associates"). The voting and dispositive control over the shares is shared by individual managing members of XV Associates, none of whom has veto power. The shares are directly held by KPCB XV Founders Fund, LLC ("KPCB XV FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XV FF is XV Associates. The voting and dispositive control over the shares is shared by individual managing members of XV Associates, none of whom has veto power. Shares held by the Michael J. Seidenberg Irrevocable Trust, established July 1, 2013, of which the Reporting Person is a trustee. Shares held by the Samuel B. Seidenberg Irrevocable Trust, established July 1, 2013, of which the Reporting Person is a trustee. Exhibit List: Exhibit 24 - Power of Attorney /s/ Jeff Kiekhofer, Attorney-in-Fact 2023-06-02 EX-24 2 brhc20053941_ex24.htm EXHIBIT 24
Exhibit 24

POWER OF ATTORNEY

The undersigned, as a Section 16 reporting person of Atara Biotherapeutics, Inc. (the "Company"), hereby constitutes and appoints Utpal Koppikar, David Tucker, Jeff Kiekhofer, Amar Murugan, John Chao and Kathleen Klaben the undersigned's true and lawful attorneys-in-fact to:

1.        Complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorneys-in-fact shall in their discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company; and

2.        Do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national association, the Company and such other person or agency as the attorneys-in-fact shall deem appropriate.

The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 (as amended).

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.

The undersigned hereby terminates all prior powers of attorney regarding the subject matter hereof.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of June 2, 2022.

 
Signature:
/s/ Beth Seidenberg
   
Beth Seidenberg, M.D.